Tofacitinib shown to be effective (vs Placebo) in 225 Polyarticular JIA (included some ERA & PsA). with less flares (29 vs 53%) and higher JCR30 responses (71 vs 47%) @6mos #EULAR2020 #OP0281 https://t.co/3BnZeB4ROr https://t.co/4pTLbTtBdN